SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2019
Commission File Number: 0-30752
Aeterna Zentaris Inc.
(Translation of registrant's name into English)
315 Sigma Drive, Suite 302D Summerville, South Carolina, USA 29486
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______.
On May 8, 2019, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1 . Press release dated May 8, 2019
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Aeterna Zentaris Inc.|
|Date: May 8, 2019||/s/ MICHAEL V. WARD|
|Michael V. Ward|
Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
CHARLESTON, S.C., May 08, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZS)
announced today at its annual and special shareholders’ meeting held on May 8, 2019, that the individuals noted below were elected as directors of the Company. The report on proxies provided by the Company’s transfer agent indicated the following:
|Name of Nominee||Votes For||%||Votes Withheld||%|
|Robin Smith Hoke||1,864,981||91.09||182,392||8.91|
The Company would like to extend its sincere thanks and best wishes to Juergen Ernst, who has served on the board of directors since 2005.
The Company reports the re-appointment of PricewaterhouseCoopers LLP as the Company's independent auditor.
The Company’s shareholders approved an ordinary resolution approving the amended and restated shareholder rights plan.
Further, the Company passed a special resolution to amend the articles of the corporation to change the province in which its registered office is situated from Quebec to Ontario.
For full voting details please see the voting results of Aeterna Zentaris Inc. as filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen (macimorelin) in the United States and Canada. For more information, visit www.zentaris.com.
Aeterna Zentaris Inc.
Chief Financial Officer